title: Recurrent priapism related to oxaliplatin infusion.
authors.forename: Antoine
authors.initials: A
authors.lastname: Adenis
authors.forename: Audrey
authors.initials: A
authors.lastname: Mailliez
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Rigot
authors.forename: Laurence
authors.initials: L
authors.lastname: Gamelin
authors.forename: Marie
authors.initials: M
authors.lastname: Vanhuyse
authors.forename: Erick
authors.initials: E
authors.lastname: Gamelin
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D017610:Calcium Compounds / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D017616:Magnesium Compounds / Q000008:administration & dosage; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D011317:Priapism / Q000139:chemically induced* / Q000517:prevention & control
chemical_list: D000970:Antineoplastic Agents; D017610:Calcium Compounds; D017616:Magnesium Compounds; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil